Browse Category

Mergers & Acquisitions 19 December 2025 - 21 December 2025

Warner Bros. Discovery (WBD) Stock Week Ahead: Netflix Deal vs. Paramount Tender Offer Keeps Shares in “Merger-Arbitrage Mode”

Warner Bros. Discovery (WBD) Stock Week Ahead: Netflix Deal vs. Paramount Tender Offer Keeps Shares in “Merger-Arbitrage Mode”

Warner Bros. Discovery, Inc. Series A stock heads into a holiday-shortened week with the kind of headline-driven volatility that rarely shows up in “normal” media earnings models. The reason is simple: WBD is now trading less like a traditional entertainment company and more like a live deal—anchored between two competing paths to a potential takeover.
21 December 2025
···
Salesforce (CRM) Stock Week Ahead: Qualified Acquisition, Agentforce Meets ChatGPT, and Analyst Price Targets to Watch (Dec. 22–26, 2025)

Salesforce (CRM) Stock Week Ahead: Qualified Acquisition, Agentforce Meets ChatGPT, and Analyst Price Targets to Watch (Dec. 22–26, 2025)

Salesforce, Inc. heads into the Christmas holiday week with a busy backdrop for investors: fresh product distribution news for its Agentforce platform, a newly announced acquisition aimed at “agentic” marketing, and a market calendar that’s likely to amplify day-to-day volatility simply because liquidity is thinner than usual.
21 December 2025
···
BioMarin (BMRN) Stock Jumps on $4.8 Billion Amicus Deal: Latest News, Forecasts and Analyst Outlook for Dec. 21, 2025

BioMarin (BMRN) Stock Jumps on $4.8 Billion Amicus Deal: Latest News, Forecasts and Analyst Outlook for Dec. 21, 2025

BioMarin Pharmaceutical Inc. is ending 2025 with a bang. Shares surged on Friday, December 19, closing at $61.15—up 17.71% on the day—after the company announced a $4.8 billion all-cash acquisition of rare-disease peer Amicus Therapeutics. Trading volume spiked to roughly 18.5 million shares, far above BioMarin’s recent daily activity, underscoring how dramatically the market repriced the story in a single session. Investing.com+2Reuters+2
21 December 2025
···
Amicus Therapeutics Stock (FOLD) News: BioMarin’s $14.50 Cash Buyout, Deal Timeline, and the Latest Forecasts (Dec. 21, 2025)

Amicus Therapeutics Stock (FOLD) News: BioMarin’s $14.50 Cash Buyout, Deal Timeline, and the Latest Forecasts (Dec. 21, 2025)

As of Sunday, December 21, 2025, Amicus Therapeutics, Inc. has effectively shifted from a “biotech story stock” to a deal-driven stock. The reason is simple and decisive: BioMarin Pharmaceutical agreed to acquire Amicus in an all-cash transaction priced at $14.50 per share, putting a hard cap on the near-term upside—unless a competing bid emerges. SEC+1
21 December 2025
···
Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Christmas week is usually about thin liquidity and shorter trading hours, not blockbuster headlines. But pharma and biotech stocks head into the final full week of the year with a rare mix of policy shockwaves, deal-making, and FDA-driven volatility—all clustered around Dec. 19–21, 2025.
21 December 2025
·········
Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $4.8B Cash Buyout at $14.50 Resets the Outlook (Dec. 20, 2025)

Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $4.8B Cash Buyout at $14.50 Resets the Outlook (Dec. 20, 2025)

December 20, 2025 — Amicus Therapeutics, Inc. has abruptly shifted from a “rare-disease growth story” to a merger-arbitrage stock after BioMarin Pharmaceutical announced a definitive, all-cash acquisition valued at roughly $4.8 billion. The headline number for shareholders: $14.50 per share in cash, a premium of about 33% to Amicus’ prior close. Reuters+2BioMarin Corporate+2
20 December 2025
···
ServiceNow (NOW) Stock News on Dec. 20, 2025: Armis Deal Rumors, 5-for-1 Split, Analyst Targets and the 2026 Outlook

ServiceNow (NOW) Stock News on Dec. 20, 2025: Armis Deal Rumors, 5-for-1 Split, Analyst Targets and the 2026 Outlook

ServiceNow, Inc. heads into the weekend with investors still digesting one of the most turbulent stretches the enterprise software leader has seen this year: a fresh stock split, a confirmed AI acquisition closing, and intense market debate over whether a rumored $7 billion cybersecurity deal would be a smart strategic leap—or an expensive distraction.
20 December 2025
···
Tether-Linked Buyers Close $200 Million Peak Mining Deal as Rumble Pursues $767 Million Northern Data Takeover

Tether-Linked Buyers Close $200 Million Peak Mining Deal as Rumble Pursues $767 Million Northern Data Takeover

December 20, 2025 — Newly surfaced U.S. regulatory filings are putting sharper names and structures behind a $200 million divestment at the center of Tether’s expanding push from crypto into AI infrastructure. Peak Mining—the bitcoin-mining business that German AI and data center operator Northern Data agreed to sell—has been acquired by three entities listed in filings as Highland Group Mining Inc., Appalachian Energy LLC, and 2750418 Alberta ULC, just as Tether-backed video platform Rumble presses ahead with an all-stock plan to acquire Northern Data. SEC+1
20 December 2025
····
BioMarin (BMRN) Stock Surges on $4.8B Amicus Deal: Latest News, Analyst Forecasts, and What to Watch Next (Dec. 20, 2025)

BioMarin (BMRN) Stock Surges on $4.8B Amicus Deal: Latest News, Analyst Forecasts, and What to Watch Next (Dec. 20, 2025)

BioMarin Pharmaceutical Inc. ended Friday’s session sharply higher after announcing a blockbuster rare-disease acquisition that immediately reframed the company’s growth story. Shares closed at $61.15, up about 17.7% on the day, with trading volume far above typical levels—classic “big-news repricing” behavior. Yahoo Finance
20 December 2025
····
Amicus Therapeutics Stock (FOLD) Surges as BioMarin Agrees to Buy the Rare-Disease Biotech for $4.8 Billion

Amicus Therapeutics Stock (FOLD) Surges as BioMarin Agrees to Buy the Rare-Disease Biotech for $4.8 Billion

December 20, 2025 — Amicus Therapeutics, Inc. is suddenly trading like a classic merger-arbitrage stock after BioMarin Pharmaceutical agreed to acquire the company in an all-cash deal valued at roughly $4.8 billion. BioMarin’s offer of $14.50 per share sparked a sharp re-pricing of Amicus shares, which have been hovering just below the bid as investors weigh deal timing, closing risk, and what the buyout means for Amicus’ two commercial rare-disease franchises—Galafold and Pombiliti + Opfolda. SEC+1
20 December 2025
·····
DJT Stock News Today: Trump Media & Technology Group Jumps on $6B TAE Fusion Merger—Price, Forecasts, and Key Risks (Dec. 20, 2025)

DJT Stock News Today: Trump Media & Technology Group Jumps on $6B TAE Fusion Merger—Price, Forecasts, and Key Risks (Dec. 20, 2025)

Dec. 20, 2025 — Trump Media & Technology Group Corp. is back in the spotlight after announcing a surprise all-stock merger with nuclear fusion company TAE Technologies—a deal the companies describe as valued at more than $6 billion and aimed at accelerating the buildout of a utility-scale fusion power plant. GlobeNewswire+1
20 December 2025
··
Trump Media (DJT) Stock Jumps After $6 Billion Fusion Merger Plan: Latest News, Forecasts, and What Investors Are Watching (Dec. 20, 2025)

Trump Media (DJT) Stock Jumps After $6 Billion Fusion Merger Plan: Latest News, Forecasts, and What Investors Are Watching (Dec. 20, 2025)

Trump Media & Technology Group Corp. is ending the week the way it often lives: loudly, unpredictably, and with traders glued to their screens. After announcing a surprise plan to merge with nuclear fusion developer TAE Technologies in a deal valued at more than $6 billion, DJT shares ripped higher on massive volume—turning a social-media stock into a new way to bet on the race to power the AI era. GlobeNewswire+2StockAnalysis+2
20 December 2025
···
Warner Bros. Discovery stock today: Netflix deal vs Paramount $30 bid, analyst forecasts, and what’s next — Dec. 20, 2025

Warner Bros. Discovery stock today: Netflix deal vs Paramount $30 bid, analyst forecasts, and what’s next — Dec. 20, 2025

Warner Bros. Discovery, Inc. stock has turned into a real-time market referendum on one question: which takeover path actually closes. As of the latest available quote, WBD shares were around $27.77, leaving the stock effectively pinned near Netflix’s agreed $27.75-per-share value while still sitting below Paramount Skydance’s $30 all-cash tender offer.
20 December 2025
····
Amicus Therapeutics Stock (FOLD) Surges After $4.8B BioMarin Buyout: $14.50 Offer, Deal Timeline, Analyst Outlook (Dec. 20, 2025)

Amicus Therapeutics Stock (FOLD) Surges After $4.8B BioMarin Buyout: $14.50 Offer, Deal Timeline, Analyst Outlook (Dec. 20, 2025)

Amicus Therapeutics, Inc. is having the kind of week biotech traders both crave and fear: a sudden, definitive catalyst that snaps the stock to a new reality overnight. On Friday, December 19, shares jumped about 30% and hovered around $14.18, after BioMarin Pharmaceutical announced a $14.50-per-share all-cash acquisition valuing Amicus at roughly $4.8 billion. Reuters+1
20 December 2025
··
Amicus Therapeutics (FOLD) Stock After Hours Dec. 19, 2025: BioMarin’s $14.50 Cash Buyout and What to Know Before the Next Market Open

Amicus Therapeutics (FOLD) Stock After Hours Dec. 19, 2025: BioMarin’s $14.50 Cash Buyout and What to Know Before the Next Market Open

Amicus Therapeutics, Inc. ended Friday’s session in a very different place than it started: the stock re-priced into “deal mode” after BioMarin Pharmaceutical announced a definitive agreement to acquire Amicus in an all-cash transaction valued at roughly $4.8 billion. BioMarin Investors+2Reuters+2
20 December 2025
··
ABM Industries (ABM) Stock Slides After Earnings: Record 2025 Revenue, WGNSTAR Acquisition, Dividend Hike and 2026 Forecasts (Dec. 19, 2025)

ABM Industries (ABM) Stock Slides After Earnings: Record 2025 Revenue, WGNSTAR Acquisition, Dividend Hike and 2026 Forecasts (Dec. 19, 2025)

ABM Industries Incorporated is ending the week with investors debating a classic market paradox: record revenue and a bigger dividend on one side, and a sharp earnings miss plus fresh analyst caution on the other. On Friday, December 19, ABM shares traded around $41.78, down about 3.9% on the day, as the market continued to digest the company’s fiscal fourth-quarter report, its $275 million WGNSTAR acquisition agreement, and new Wall Street commentary.
19 December 2025
··
ServiceNow (NOW) Stock Today: Post-Split Trading, Armis Deal Talk, Analyst Targets, and What Wall Street Is Watching on Dec. 19, 2025

ServiceNow (NOW) Stock Today: Post-Split Trading, Armis Deal Talk, Analyst Targets, and What Wall Street Is Watching on Dec. 19, 2025

ServiceNow, Inc. is back in the spotlight on December 19, 2025—this time for a mix of market mechanics and strategy that rarely collide so loudly in a single week: a fresh 5-for-1 stock split, unusually sharp volatility tied to blockbuster M&A rumors, and a renewed debate about how quickly enterprise software leaders can turn “agentic AI” into real, recurring dollars.
19 December 2025
··
DJT Stock News Today: Trump Media Shares Jump Again on Dec. 19 as $6 Billion TAE Fusion Merger Sparks Fresh Volatility

DJT Stock News Today: Trump Media Shares Jump Again on Dec. 19 as $6 Billion TAE Fusion Merger Sparks Fresh Volatility

Dec. 19, 2025 — Trump Media & Technology Group Corp. is trading sharply higher again on Friday, extending a stunning two-day move after the Truth Social parent announced an all-stock merger with nuclear fusion company TAE Technologies—a pivot that has Wall Street, retail traders, and policy watchers parsing the fine print in real time. Reuters
19 December 2025
··
1 2 3 4 5 6 … 20
Follow on Google News
Add as preferred source Open in Google News
AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 BUY ON PULLBACK

Microsoft

NASDAQ: MSFT 94 / 100
#2 BUY

L3Harris Technologies

NYSE: LHX 90 / 100
#3 BUY

Xylem

NYSE: XYL 89 / 100
#4 BUY IN TRANCHES

Lam Research

NASDAQ: LRCX 87 / 100
#5 BUY ON WEAKNESS

GE HealthCare

NASDAQ: GEHC 84 / 100
View full portfolio
Editorial model selection. Not personalised advice.